Rx00125 - Iloprost


Name:
Iloprost
Rx ID:
Rx00125
Validation Level:
Reference ID:
DB01088
Primary Indications:
Pulmonary arterial hypertension
Orphan Indications:
No annotated orphan indications.
Rare Indications:
Raynaud's phenomenon; systemic sclerosis; heparin-associated thrombocytopenia
Common Indications:
Pulmonary arterial hypertension
Pathways:
Beta2 integrin cell surface interactions
Drug Interactions:
Trandolapril;
Food Interactions:
No annotated food interactions in DrugBank.

Interactive 3D Model

Interactive Drug Target Network

Interactive Bipartite Drug Repurposing Graph

Rx00125
Primary Indication
Secondary Indication

Visualize Chemical Properties

Select x-axis

Select y-axis

Disease prevalence from Electronic Health Records

Click row to show all

Disease A Disease B A∩B A∩¬B B∩¬A Odds-Ratio P-Value Adjusted P-Value
pulmonary arterial hypertension systemic sclerosis 181 5023 975 149.124 0.00E+00 7.22e-306

Chemical, Pharmacological and Biological Annotations


ATC Code:
B01AC11
Categories:
No categories annotated in DrugBank
PubChem ID:
6443959
SMILE:
CC#CCC(C)C(O)\C=C\C1C(O)CC2C\C(CC12)=C\CCCC(=O)OCC(=O)C1=CC=CC=C1
InChI:
1S/C30H38O5/c1-3-4-10-21(2)27(31)16-15-25-26-18-22(17-24(26)19-28(25)32)11-8-9-14-30(34)35-20-29(33)23-12-6-5-7-13-23/h5-7,11-13,15-16,21,24-28,31-32H,8-10,14,17-20H2,1-2H3/b16-15+,22-11-
Classification:
Kingdom:
Organic Compounds
Superclass:
Lipids
Class:
Eicosanoids
Subclass:
Prostaglandins and related compounds
Indication:
Used for the treatment of pulmonary arterial hypertension.
Pharmacodynamics:
Iloprost is a synthetic analogue of prostacyclin PGI2. Iloprost dilates systemic and pulmonary arterial vascular beds. It also affects platelet aggregation but the relevance of this effect to the treatment of pulmonary hypertension is unkno...
Click to show more...
Description:
Iloprost is a synthetic analogue of prostacyclin PGI2. Iloprost dilates systemic and pulmonary arterial vascular beds. It is used to treat pulmonary arterial hypertension (PAH).
Mechanism:
Iloprost is a second generation structural analog of prostacyclin (PGI) with about ten-fold greater potency than the first generation stable analogs, such as carbaprostacyclin. Iloprost binds with equal affinity to human prostacyclin (Prost...
Click to show more...

Adsorption, Distribution, Metabolism, Excretion and Toxicity


Human Intestinal Absorption:
+
Blood Brain Barrier:
+
Caco-2 permeable:
+
P-glycoprotein substrate:
Substrate
P-glycoprotein inhibitor I:
Non-inhibitor
P-glycoprotein inhibitor II:
Non-inhibitor
Renal organic cation transporter:
Non-inhibitor
CYP450 2C9 substrate:
Non-inhibitor
CYP450 2D6 substrate:
Non-inhibitor
CYP450 2C19 substrate:
Non-inhibitor
CYP450 inhibitory promiscuity:
Low CYP Inhibitory Promiscuity
Ames test:
Non AMES toxic
Carcinogenicity:
Non-carcinogens
Biodegradation:
Not ready biodegradable
Rat acute toxicity:
2.7260 LD50, mol/kg
hERG inhibition (predictor I):
Weak inhibitor
hERG inhibition (predictor II):
Non-inhibitor

Contact Us:
Please contact us if you have questions or comments about RepurposeDB. You can also contact us if you need help in submitting your drug repositioning investigation to RepurposeDB.


Dudley Laboratory
Department of Genetics and Genomic Sciences
Icahn Institute for Genomics and Multiscale Biology
Icahn School of Medicine at Mount Sinai
One Gustave L. Levy Place, Box 1498
Manhattan, New York City, NY
repurposedb@dudleylab.org